Real-World Sotatercept Eligibility: Analysis from the FOCUS-PAH Registry
Respiration · 12.06.2026 · 1-11
DOI: 10.1159/000552663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 12.06.2026. Verfasst von Giulio Savonitto und 35 weiteren Autor:innen. Beteiligte Einrichtung: Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) and University Hospital of Trieste, Trieste, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Pulmonary arterial hypertension (PAH) remains burdened by suboptimal outcomes despite contemporary therapy. Sotatercept showed clinical benefit in STELLAR and ZENITH, yet trial criteria may limit real-world implementation. We quantified real-world eligibility at baseline and during follow-up and identified baseline predictors of non-eligibility.
Methods
We retrospectively analyzed 657 patients with incident PAH (2001–2024), excluding 116 with incomplete follow-up data. Inclusion criteria mirroring STELLAR were WHO functional class II/III, PVR ≥5 WU, and stable background therapy. Exclusion criteria included severe comorbidities or recent cardiovascular events. Multivariable models identified predictors of non-eligibility. Extended eligibility per ZENITH criteria was also assessed.
Results
Among 541 analyzed patients, 104 (19%) were ineligible at baseline, mainly due to non-permitted PAH subtypes (71%) or vasoreactivity (29%). During a median 45-month follow-up, cumulative follow-up eligibility (i.e., patients who met criteria at least once after baseline) was 50%, with most exclusions due to PVR
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) and University Hospital of Trieste, Trieste, Italy.
- Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, UK.
- Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
- Division of Cardiology, Cardiovascular and Thoracic Department of Medical Sciences, "Città della Salute e della Scienza" Hospital, Turin, Italy.
- De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.
- School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Zitieren
APA
Savonitto, G., Santi, G., Pagnesi, M., Bocchino, P. P., Gentile, P., Acquaro, M., Driussi, M., D Apos Angelo, L., Macera, F., Howard, L. S., Toma, M., Miceli, G., Barbisan, D., Collini, V., Lombardi, C. M., Bauleo, C., Rugolotto, M., Bertarelli, E., Pagnoni, G., …, & Stolfo, D. (2026). Real-World Sotatercept Eligibility: Analysis from the FOCUS-PAH Registry. Respiration, 1-11. https://doi.org/10.1159/000552663
Vancouver
Savonitto G, Santi G, Pagnesi M, Bocchino PP, Gentile P, Acquaro M, et al. Real-World Sotatercept Eligibility: Analysis from the FOCUS-PAH Registry. Respiration. 2026:1-11. doi:10.1159/000552663
BibTeX
@article{Savonitto2026,
author = {Savonitto, Giulio and Santi, Giovanni and Pagnesi, Matteo and Bocchino, Pier Paolo and Gentile, Piero and Acquaro, Mauro and Driussi, Mauro and D Apos Angelo, Luciana and Macera, Francesca and Howard, Luke S and Toma, Matteo and Miceli, Gaia and Barbisan, Davide and Collini, Valentino and Lombardi, Carlo Maria and Bauleo, Carolin and Rugolotto, Matteo and Bertarelli, Elena and Pagnoni, Gianluca and Bobbio, Emanuele and Bartfay, Sven-Erik and Wermström, Johanna and Scelsi, Laura and Giannoni, Alberto and Vani, Suela and Imazio, Massimo and Airo, Edoardo and Coppi, Francesca and Raineri, Claudia and Metra, Marco and Garascia, Andrea and Hjalmarsson, Clara and Sinagra, Gianfranco and Lo Giudice, Francesco and Ameri, Pietro and Stolfo, Davide},
title = {Real-World Sotatercept Eligibility: Analysis from the FOCUS-PAH Registry},
journal = {Respiration},
year = {2026},
pages = {1--11},
doi = {10.1159/000552663}
}
EUVIMED